All the below links and tweets are in English.
取り急ぎ以下貼っておきます。
New York Vol.35 (corporations: Pfizer)
New York Vol.36 (corporations: Bristol Myers Squibb)
New York Vol.37 (corporations: Regeneron)
ツイッター検索で 上記3製薬会社各社 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
AFIB awareness month – learn more here and spread the word. #Bayer #Daiichi-Sankyo #BMS #Pfizer https://t.co/v8seSL6y3u
— Medable (@medableinc) September 24, 2020
#XTANDI #news
Pfizer and Astellas announced the final results of the overall analysis from Phase 3 PROSPER study#asco20 #asco2020 #oncology #pharmanews #pfizer #astellas #conferences #consultingservices https://t.co/Tj2z4xc0rn— ipharmacenter (@ipharmacenter) May 30, 2020
Insights on the Worldwide Antihypertensive Drugs Industry to 2026 – Players Include Pfizer, Takeda Pharmaceutical & AstraZeneca Among Others – https://t.co/8vPVgQlQhj https://t.co/bzOL6dTM2O
— Pharmacutical Daily (@PharmacDaily) April 6, 2020
Pfizer, Astellas' Xtandi scores Bayer-matching win in extending prostate cancer patients' lives. Can Pfizer and Astellas leverage this data into building Xtandi as the market leader in castration-resistant #prostatecancer? #pcsm $PFE https://t.co/r6Qu9NOoll pic.twitter.com/8EiTRmgIxE
— Bionest Partners (@BionestPartners) February 12, 2020
FDA approves expanded label for Pfizer, Astellas' prostate cancer therapy Xtandi https://t.co/fCFTjO9ita
— Stuart Edmonds (@stuartd_e) December 19, 2019
Great turnout for our Siemens Sitrain TIA Portal Service 1 course. Patrick Martin from Siemens SITRAIN Manchester @siemensuknews was the trainer & participants came from #EirGen, #Pfizer, #Takeda & #IMALife. The course will run again in Feb '20: https://t.co/8uD3AVwAWq(tia-s.aspx pic.twitter.com/2FETEXmR6E
— Engineers Ireland (@EngineerIreland) December 5, 2019
ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging tech, writes @pharmaphorum https://t.co/ZBtv9FxFG3
— ImaginAbInc (@ImaginAbInc) October 14, 2019
Pfizer, Astellas win priority review for Xtandi sNDA; Hemispherx changes its name https://t.co/p50wHHb5X1 $PFE
— Endpoints News (@endpts) August 24, 2019
Parenteral Nutrition Market 2019: Industry Analysis and Detailed Profiles of Top Industry Players B. Braun Melsungen AG, Fresenius Kabi AG, ALLERGAN, Grifols, S.A., Pfizer Inc., Otsuka Pharmaceutica https://t.co/Asz3gkZp3s pic.twitter.com/NfOrepvOzK
— PressRelease.cc (@PressRelease_cc) May 21, 2019
See how #Pfizer, #AstraZeneca, #Sanofi, #Astellas and more are achieving real patient centric processes in these free panels from our 2019 patient track https://t.co/RYUehW8IOL
— Reuters Events Pharma (@RE_Pharma) October 11, 2019
@pfizer or Otsuka. Which company do you admire the most? Vote here: https://t.co/2YWu39L6xM #mostadmiredpharma pic.twitter.com/WKI5AzT7pR
— Reuters Events Pharma (@RE_Pharma) January 10, 2017
#Pfizer, #Astellas’ #Xtandi significantly improves #OS in phase 3 #prostatecancer study https://t.co/Sl5SywJbvp via @Pharma_BR @pfizer @AstellasUS @pfizer_news
— Plexus Ventures (@PlexusVentures) February 13, 2020
Pfizer, Astellas' Xtandi scores Bayer-matching win in extending prostate cancer patients' lives https://t.co/6Cf4Ow9STS
— FiercePharma (@FiercePharma) February 11, 2020
J&J's Erleada scores metastatic prostate cancer nod in battle with Pfizer-Astellas' Xtandi https://t.co/Eig4GG22N9
— FiercePharma (@FiercePharma) September 18, 2019
Pfizer, Astellas rocket toward broader Xtandi use with FDA 'priority' tag https://t.co/KcOPOyolpw
— FiercePharma (@FiercePharma) August 22, 2019
Pfizer, Astellas chase new Xtandi nod with big survival numbers in prostate cancer https://t.co/x2nz46FY1l
— FiercePharma (@FiercePharma) February 12, 2019
The deals with Novartis, Otsuka, Pfizer and Sanofi will boost its ecosystem and “could help foster greater scientific discovery” as the pharma companies work on “next-generation research and development programs,” Verily said: https://t.co/h6tD7yJiaf
— FierceBiotech (@FierceBiotech) May 21, 2019
Prostate cancer shake-up looms with new data from Pfizer, Astellas and Johnson … https://t.co/reOTWifrUC $JNJ #stocks #stockmarket
— StockMarketScoop (@StockScoops) February 26, 2019
Japan has signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech, which is developing the drug with US pharma giant Pfizer, said. https://t.co/crihB500gj
— Philstar.com (@PhilstarNews) August 1, 2020
More updates to @nytimes vaccine tracker: Sanofi makes a deal to supply US with protein vaccines, Pfizer makes a deal with Japan, Vaxine finishes Phase I trials, and monkeys get protection from Moderna and J&J shots. https://t.co/8RbPgaLziS
— Carl Zimmer (@carlzimmer) July 31, 2020
Pfizer, BioNTech to supply 120 million doses of coronavirus vaccine to Japan https://t.co/CPE5UL5WWR pic.twitter.com/iphKs1StYM
— Reuters (@Reuters) July 31, 2020
Pfizer Japan recalls high blood pressure drug over cancer-causing impurity https://t.co/9LdUeUtJi0 pic.twitter.com/mo0igvh0Hb
— Reuters (@Reuters) February 8, 2019
Pfizer Japan recalls its high blood pressure drug Amvalo containing the API valsartan after possible carcinogenic impurities were found. https://t.co/g7iIuIf8Wl
— ConsumerSafetyWatch (@consumersafetyw) February 11, 2019
Pfizer Japan drawn into valsartan recall after finding API from Mylan is tainted #Pharma https://t.co/6bR5IJSo4L
— Varadharajan K PhD (@VaradhKrish) February 13, 2019
Pfizer Japan Cautious Over New Policies As Sales Slip https://t.co/WCU1uOPqqO
— Ian Haydock (@ScripIanHaydock) March 2, 2018
Pfizer expands Japan contracting offering touting market knowhow https://t.co/5WwiesSuTE #onmedic #ehealth #pharma
— onmedic global (@onmedicglobal) October 23, 2017
From the Pfizer Photo Archives: A sales rep discusses medicines with a pharmacist in Nagoya, #Japan (1967) pic.twitter.com/b864XJQgSq
— Pfizer Inc. (@pfizer) March 5, 2016
From the Pfizer Photo Archives: Sales reps at Pfizer #Japan prepare for a busy day of appointments (1963) pic.twitter.com/lCLRWnW3wc
— Pfizer Inc. (@pfizer) February 6, 2016
Pfizer Japan matches PFE colleague donations to fund recovery efforts from devastating #NepalEarthquake pic.twitter.com/HoRjVNyJ0W
— Pfizer Inc. (@pfizer) August 21, 2015
Anti-Obesity Prescription Drugs Market Future Scenario, CAGR, Key Developments and Size|Bristol-Myers Squibb Co., Takeda Pharmaceutical., Eisai Company.https://t.co/UqYXeQUzeB#news #pharma #pharmiweb
— Pharma News (@pharminews) September 22, 2020
Bristol-Myers Squibb, Takeda and Daiichi Sankyo shot up rankings of top 20 pharma companies by market cap, according to a new GlobalData analysis https://t.co/EJc7SrNBnM
— pharmaphorum (@pharmaphorum) June 22, 2020
MedNess this week features bite size news on:
BioMarin’s hemophilia A candidate accepted for FDA priority review
Japan Approves Bristol-Myers Squibb's Opdivo for Esophageal Cancer
FDA Issues Complete Response Letter for sBLAs…https://t.co/oLDevWice6 https://t.co/AYfj4HBTeX
— Ananda Ghosh, PhD (@andz79) February 26, 2020
Professionals from Becton Dickinson, Astellas, Novartis, Bristol-Myers Squibb, and more convene at Novo Nordisk headquarters for the upcoming 15th Public Relations & Communications Summit. https://t.co/pCJ7YBFjlF
— Fierce Life Sciences Events (@LifeSciEvents) April 30, 2019
Roche says 'no thanks' to megadeals, but don't count out smaller M&A: After two recent, huge tie-ups between Takeda and Shire and Bristol-Myers Squibb and Celgene, megamergers seem to be a biopharma trend. But Roche isn't interested, its chairman said. https://t.co/BAAOw2Wgks
— cafepharma (@cafepharma) January 22, 2019
Taisho Pharmaceutical will acquire the French over-the-counter drugmaker UPSA from Bristol-Myers Squibb, the latest move by Japan's top seller of nonprescription medicines to expand overseas. https://t.co/hDgtCvt9Xr
— Nikkei Asian Review (@NAR) December 19, 2018
Immunosuppressants Market Impressive Growth 2019 | GlaxoSmithKline plc, Novartis AG, Sanofi, Bristol-Myers Squibb Company, Pfizer Inc., Astellas Pharma Inc., Zydus Cadila https://t.co/UgRU3aWvgK pic.twitter.com/zRdA3OAcP7
— ABNewswire (@ABNewswire) September 13, 2019
Thymus Cancer Market to Grow exponential with Astellas Pharma | Astrazeneca | Bristol-Myers Squibb | Takeda pharmaceutical company, etc. – Asserts MRFR Unleashing Industry Forecast to 2024 https://t.co/j0Lby60IiK pic.twitter.com/t40OOZcXlh
— ABNewswire (@ABNewswire) May 9, 2018
Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment: PRINCETON, N.J. & OSAKA, Japan–(BUSINESS WIRE)–$BMY–Bristol-Myers Squibb Granted Exclusive… https://t.co/tDraaRo0Yy pic.twitter.com/FZjSnGbDS1
— Business Wire-Health (@BW_Health) December 13, 2017
Bristol-Myers Squibb and Otsuka Pharmaceutical have reached a global settlement with plaintiffs in multidistrict litigation over side effects of their antipsychotic drug Abilify. https://t.co/Cxi3FktGho pic.twitter.com/pNGBz0wMFy
— Law360 (@Law360) February 26, 2019
Bristol-Myers Squibb, Daiichi Sankyo to Jointly Test Opdivo/DS-8201 Combo in HER2+… https://t.co/cnBZiI9qa3 pic.twitter.com/M95ccszHnv
— Immuno-Oncology News (@immunooncnews) September 5, 2017
Bristol-Myers Squibb starts research collaboration with Eisai – https://t.co/iKI2PJKO1q pic.twitter.com/m5oXPiRSCQ
— GMPnews.Net (@GMPnewsNet) December 17, 2018
https://twitter.com/UMCGlobalSafety/status/1180090377161908224
8-25-2020: Starting 4 months from now, Lilly's LY-CoV555, Regeneron's REGN-COV2, AstraZeneca's AZD7442, or Takeda/Behring/Octapharma might work for early COVID-19, be expensive, be vulnerable to mutations, and be in short supply:https://t.co/s29UYtb9o3https://t.co/ijHm26afc3
— Ronald M. Chavin (@rmchavin) August 25, 2020
Adimab broadens R&D deals with Novartis, Regeneron, Takedahttps://t.co/9gF1SqcuEq#R&D #novartis #regeneron #takeda #health #healthcare #pharmaceutical #digitalhealth #vitalyhealth
— Vitaly Health (@HealthVitaly) May 19, 2019
Adimab broadens R&D deals with Novartis, Regeneron, Takeda https://t.co/PLAwHC7tjz career medical device pic.twitter.com/cbGNbtODv1
— ThinKeen Global (@thinkeenglobal) May 8, 2019
Takeda and Regeneron continue to tap into Adimab’s capabilities https://t.co/lIicDWO57S pic.twitter.com/bUbVGC5pmH
— JackLeckerman (@JackLeckerman) May 13, 2019
“Regeneron (REGN) Reports Approval of DUPIXENT in Japan for Treatment of Atopic Dermatitis” https://t.co/kUdtuobA6v pic.twitter.com/2YRe5IDgEO
— Juan C Ivancevich MD (@Aller_MD) January 22, 2018
13 co's working on Coronavirus treatments/vaccines. Gilead's remdesivir is in late stage testing, GlaxoSmithKline is collaborating with Britain, U of Queensland. See also, Heat Biologics, Inovio, Johnson & Johnson, Moderna, Regeneron, Sanofi, Takeda, more. https://t.co/NyT4jixMES
— Dori Smith (@Dori_TalkNation) March 17, 2020
Biopharma's ever-evolving #COVID19 response, distilled:
Gilead, AbbVie, Pfizer looking at antivirals
J&J, Sanofi, and Moderna on vaccines
Regeneron, Eli Lilly, and Vir on antibodies
Takeda and Emergent on plasma therapyhttps://t.co/8S4Ucbc6ef— Andrew Dunn (@AndrewE_Dunn) March 13, 2020
